GeneDx Holdings Corp. (NASDAQ:WGS – Get Rating) Director Richard C. Pfenniger, Jr. acquired 5,000 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was acquired at an average price of $5.90 per share, for a total transaction of $29,500.00. Following the completion of the purchase, the director now owns 5,918 shares of the company’s stock, valued at approximately $34,916.20. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
GeneDx Price Performance
NASDAQ WGS opened at $7.34 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.18 and a current ratio of 2.29. GeneDx Holdings Corp. has a one year low of $5.73 and a one year high of $81.84. The firm’s fifty day moving average is $8.81 and its two-hundred day moving average is $11.77.
GeneDx (NASDAQ:WGS – Get Rating) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($1.17). GeneDx had a negative return on equity of 115.70% and a negative net margin of 238.09%. The firm had revenue of $43.14 million for the quarter, compared to analyst estimates of $37.90 million. On average, analysts forecast that GeneDx Holdings Corp. will post -5.9 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
GeneDx Company Profile
Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn.
- Get a free copy of the StockNews.com research report on GeneDx (WGS)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.